PFIZER CANADA STRENGTHENS FIGHT AGAINST PNEUMONIA
By Adnews Staff
Pfizer Canada Inc. of Kirkland, Que. has launched the next step in the fight against pneumonia with the release of a new antibiotic called TROVAN (trovafloxacin). TROVAN is expected to play a role in the treatment of community-acquired pneumonia, a potentially fatal lung infection which causes 7,000 deaths and affects nearly 360,000 Canadians each year. TROVAN was approved for sale in Canada in early December and was available to patients earlier this week. It is a fourth generation quinolone and is the first antibiotic to have activity against all four pathogens. In infections like pneumonia, doctors find it extremely difficult to determine the bacteria causing the infection. TROVAN allows doctors to use one antibiotic to cover the likely pathogens, including the increasing number of bacteria that have become resistant to traditional antibiotics. Advertising for the new treatment will be done by Healthcare Marketing Resources of Montreal. Print ads will appear in medical journals and will be targeted to the medical community and health care professionals. Jasmin et associes of Montreal is handling PR.